Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S5BV
|
|||
| Former ID |
DNCL001605
|
|||
| Drug Name |
ABT-652
|
|||
| Indication | Diabetic neuropathy [ICD-11: 8C0Z] | Phase 2 | [1] | |
| Musculoskeletal pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Phase 2 | [1] | ||
| Company |
Abbott Laboratories
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01207115) A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.